ODTX earnings analysis
What we found in ODTX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Odyssey Therapeutics, Inc. reported a net loss of $38.3 million for Q1 2026, a slight improvement compared to the $38.4 million loss a year earlier. Revenue was reported as zero for the quarter, compared to $1.9 million from partnership agreements in Q1 2025. Key progress includes the achievement of clinical proof-of-concept for their oral RIPK2 inhibitor OD-001 in ulcerative colitis, alongside maintaining a strong cash position of approximately $175.7 million, projected to fund operations into late 2028.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Improvement in Net Loss
- Net loss improved slightly to $38.3 million in Q1 2026 from $38.4 million in Q1 2025.
- Strong Cash Position
- Cash, cash equivalents, and marketable securities totaled $175.7 million as of March 31, 2026.
- Clinical Proof-of-Concept Achieved
- Achieved proof-of-concept for OD-001 in a trial for moderate to severe ulcerative colitis.
- Reduced R&D Expenses
- Research and development expenses decreased by $6.5 million to $32.3 million from $38.8 million year-over-year.
- Positive Cash Flow from Investing Activities
- Net cash provided by investing activities reached approximately $34.8 million.
- Increased Interest Income
- Interest income rose to $1.7 million from $1.2 million year-over-year.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- No Revenue Generation
- The company reported zero revenue for Q1 2026, down from $1.9 million from collaborations in Q1 2025.
- Continuous Operating Losses
- Firm has incurred significant net losses, with an accumulated deficit of $606.4 million as of March 31, 2026.
- Dependence on Third-Party Manufacturers
- Reliance on external manufacturers poses risks related to compliance and dependency on their capabilities.
What they said about what is next.
The company anticipates continued R&D expense increases but does not provide explicit guidance on revenue or EPS.
The filing reads about the same as the one before it.
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ODTX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever